		Age (weeks)									
Lab/Screen	Methods	7	8	9	10	11	12	13	14	15	16
Behaviour	Openfield										
	Acoustic startle response & PPI										
Neurology	Modified SHIRPA, grip strength										
	Rotarod										
Dysmorphology	Anatomical observation										
Energy Metabolism	Indirect calorimetry										
Cardiovascular	Awake ECG / Echo cardiography										
Clinical Chemistry	IpGTT										
Neurology	Auditory brain stem response (ABR)										
Dysmorphology	X-Ray, DEXA										
Еуе	Scheimpflug imaging, Laser-interference-biometry (LIB), Optical coherence tomography (OCT), Virtual drum test										
Clinical Chemistry	Clinical Chemical analysis, hematology										
Immunology	Flow cytometry, plasma (IgE, IL6, TNF, insulin)										
Pathology	Macro & microscopic analysis										

Fig. S1. Phenotyping pipeline used to analyse Dhx9 -/- mice showing category and test performed and mouse age in weeks at testing



DHX9 interactome - https://string-db.org/

	Nuclear localization signal																		
H. sapiens	Y	G	D	G	Р	R	Р	Р	K	м	A	R	Y	D	N	G	s	G	Y
P. troglodytes	Y	G	D	G	Ρ	R	P	Р	ĸ	м	A	R	Y	D	N	G	s	G	Y
M. mulatta	Y	G	D	G	P	R	P	P	ĸ	м	Α	R	Y	D	N	G	s	G	Y
P. hamadryas	Y	G	D	G	Ρ	R	Р	Р	ĸ	м	A	R	Y	D	N	G	s	G	Y
B. taurus	Y	G	D	G	Ρ	R	Ρ	Р	ĸ	м	A	R	Y	D	N	G	S	G	Y
E. caballus	Y	G	D	G	Ρ	R	Р	Р	ĸ	м	A	R	Y	D	N	G	s	G	Y
C. lupus familiaris	Y	G	D	G	Р	R	Ρ	Ρ	ĸ	м	A	R	Y	D	N	G	G	G	Y
M. musculus	Y	G	D	G	Р	R	Ρ	Ρ	ĸ	м	A	R	Y	D	N	G	s	G	Y
R. norvegicus	Y	G	D	G	Р	R	Ρ	Ρ	ĸ	м	A	R	Y	D	N	G	s	G	Y
L. africana	Y	G	D	G	Р	R	Ρ	Ρ	ĸ	м	A	R	Y	D	N	G	s	G	Y
D. novemcinctus	Y	G	D	G	Р	R	Ρ	Ρ	к	м	A	R	Y	D	N	G	s	G	Y
A. carolinensis	Y	G	D	G	Ρ	R	Ρ	Ρ	к	м	A	R	Y	D	N	G	G	G	Y
D. rerio	F	G	D	G	Ρ	R	Р	Р	ĸ	м	A	R	т	D	F	G	G	G	F

Predicted NLSs in query sequence

IVLVDDWIKLQISHEAAACITGLRAAMEALVVEVTKQPAIISQLDPVNER	50
MLNMIRQISRPSAAGINLMIGSTR <mark>YGDGPRPPKMARYDNGSGY</mark> RRGGSSY	100
SGGGYGGGYSSGGYGSGGYGGSANSFRAGYGAGVGGGYRGVSRGGFRGNS	150
GGDYRGPSGGYRGSGGFQRGGGGRGAYGTGYFGQGRGGGGGY	190



Predicted NLSs in query sequence

IVLVDDWIKLQISHEAAACITGLRAAMEALVVEVTKQPAIISQLDPVNER 50 MLNMIRQISRPSAAGINLMIGSTRYGDGPRPPRMARYDNGSGYRRGGSS 100 SGGGYGGGYSSGGYGSGGYGGSANSFRAGYGAGVGGGYRGVSRGGFRGNS 150 GGDYRGPSGGYRGSGGFQRGGGRGAYGTGYFGQGRGGGGGY 190



#### D) p.(Arg1166Pro)

Predicted NLSs in query sequence

IVLVDDWIKLQISHEAAACITGLRAAMEALVVEVTKQPAIISQLDPVNER 50 MLNMIRQISRPSAAGINLMIGSTRYGDGPRPPKMAPYDNGSGYRRGGSSY 100 SGGGYGGGYSSGGYGSGGYGGSANSFRAGYGAGVGGGYRGVSRGGFRGNS 150 GGDYRGPSGGYRGSGGFQRGGGRGAYGTGYFGQGRGGGG 189



#### A)

C)



∆ type	∆ score ⑦	pre-mRNA position ⑦
Acceptor Loss	0.02	4 bp
Donor Loss	0.01	50 bp
Acceptor Gain	0.14	18 bp
Donor Gain	0.00	

EGFP





p.(Ala1255Thr) (CMT)

B DAPI DSB

R-loop

p.(Gly411Glu) (mild NDD)























### p.(Val473lle) (mild NDD)

#### p.(Arg761GIn) (mild NDD)









lpGTT results	female		m	ale	linear model	linear model	linear model
	con	mut	con	mut	genotype	sex	genotype:sex
	n=26	n=9	n=19	n=6			
	mean ± sd	mean ± sd	mean ± sd	mean ± sd	p-value	p-value	p-value
Glucose (T=0)	$5.35 \pm 0.81$	$5.42 \pm 0.56^{a}$	6.23 ± 1.04	6.03 ± 1.27	0.822	0.014	0.664
AUC 0-30	295.39 ± 94.35	330.05 ± 74.5 <sup>a</sup>	366.05 ± 51.65	384.82 ± 65.12 <sup>a</sup>	0.302	0.018	0.758
AUC 30-120	417.75 ± 176.08	551.57 ± 208.3ª	724.27 ± 183.29	1050.96 ± 226.25 <sup>a</sup>	< 0.001	< 0.001	0.123

Fig. S8. Loss of Dhx9 in mice causes differences in clinical chemistry indices indicative of altered metabolism and renal function



Fig. S9. Loss of *Dhx9* in mice causes haematological alterations indicative of effects on erythropoiesis and thrombopoiesis

#### **Supplemental Table 1**

Assay	Age (weeks)	Number (n)							
		+	-/+	-/-					
		Males	Females	Males	Females				
Open field	8	19	26	6	9				
SHIRPA	9	19	26	6	9				
Grip strength	9	19	26	6	9				
Acoustic startle	10	19	26	6	9				
Indirect calorimetry	11	18	26	6	9				
Glucose tolerance test	13	19	26	6	9				
Auditory brainstem response	14	14	16	4	4				
Clinical chemistry/hematology	16	19	26	6	9				

**Table S1.** Number of *Dhx9* -/- tested in the assays where relevant differences were detected.

### Supplemental Table 2

Variant Type (Patient ID)	Disease Type	Severity	DHX9 location	DSB pattern and level	R-loop pattern and level
WT	-	-	Diffuse nuclear	Scattered, low	Gathered, +
Truncating (9,10,M42-1)	NDD	Mild	Whole cell	Ubiquitous, +	Gathered, +
NLS missense (3,5)	NDD	Severe	Cytoplasm only	Ubiquitous, +	Gathered, +
Missense (1)	NDD	Severe	Diffuse nuclear	Ubiquitous, ++	Ubiquitous, ++
Missense (2,4,8,11)	NDD	Mild	Diffuse nuclear or nucleolar	Ubiquitous, low	Gathered, low
Missense (15,16,17)	СМТ	-	Nucleolar	Ubiquitous, low	Gathered, low

### **Supplemental Table 3**

	Abso			
Transfected expression plasmid	Trial 1	Trial 2	Trail 3	Average
No transfection blank	0.442	0.441	0.441	0.441
EGFP-backbone	0.435	0.342	0.343	0.373
EGFP-DHX9 WT	0.646	0.647	0.66	0.651
DHX9 p.R229*	0.377	0.433	0.417	0.409
DHX9 p.G411E	0.457	0.419	0.466	0.447
DHX9 p.V473I	0.628	0.653	0.634	0.638
DHX9 p.C608G	0.648	0.688	0.656	0.664
DHX9 p.E693Gfs*7	0.438	0.358	0.421	0.406
DHX9 p.R764*	0.41	0.447	0.428	0.428
DHX9 p.R761Q	0.6	0.614	0.593	0.602

#### Supplemental Text

Limited clinical details were available for three individuals: two within the BHCMG/GREGOR, BAB4646 and M42-1, and a patient from a simplex autism spectrum disorder (ASD) cohort<sup>19</sup>. BAB4646 and M42-1 have the only two *DHX9* pLoF variants within the BHCMG database of 12,266 exomes and genomes. BAB4646's phenotype is severe DD/ID and primary immunodeficiency. Proband ES identified two heterozygous pathogenic variants in *TRNT1*(NM\_182916.2): c.1246A>G, p.(Lys416Glu) and c.608+1G>T. As *TRNT1* causes autosomal recessive syndrome sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay [MIM: 616084], these variants likely contribute to the individual's DD/ID and immunodeficiency. Further confirmation of this contention was obfuscated by the lack of additional DNA samples from the proband or his parents precluding variant phasing and determination of *de novo* status.

Subject M42-1 was enrolled in a mitochondrial disease cohort and is one of two affected siblings with encephalopathy, stroke-like episodes, and drug-resistant epilepsy. Proband ES failed to identify a candidate variant to explain the patient's mitochondrial disease, and sibling DNA is not available for testing. While *DHX9* pLoF variants are unlikely to completely explain the phenotypes of BAB4646 and M42-1, they may contribute to their neurologic dysfunction via multi-locus pathogenic variation to a blended traits phenotype<sup>53</sup>.